Eli Lilly announced that the Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) significantly improved event-free survival by reducing the risk of recurrence or death by 83% compared to placebo in early-stage RET fusion-positive non-small cell lung cancer patients. This is the first proven targeted adjuvant therapy for this patient group, highlighting the need for comprehensive biomarker testing at diagnosis. The results, to be published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting, may change clinical practice by establishing Retevmo as a new standard of care after surgery or radiation.
The FDA has approved Eli Lilly's Jaypirca (pirtobrutinib) for use as a first-line treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without the 17p deletion. This approval is ...
Eli Lilly reported a 47.7% revenue increase to $22.97 billion in Q2 2026, surpassing expectations and raising its full-year revenue guidance to $85-$87 billion. The company’s stock trades near $1,185 with a 24/7 Wall St. price target of $1,401, sugge...
Eli Lilly announced promising mid-stage trial results for EloraTZP, a new obesity drug that led to up to 23.3% weight loss in overweight or obese type 2 diabetes patients after 48 weeks, outperforming Novo Nordisk's tirzepatide alone. The drug also s...
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
Eli Lilly's Foundayo (orforglipron) showed in post-hoc analyses of the ATTAIN-1 trial a significant reduction in predicted 10-year risks of type 2 diabetes and cardiovascular disease among adults with obesity or overweight with related health issues....
